Nov 29, 2024 | Uncategorized
Imidex’s Technology is a Front-End Patient Acquisition Tool for Healthcare Providers Targeting Early Lung Cancer Detection, Achieving 83% Sensitivity in Identifying Lung Nodules in Chest X-rays. DENVER, Nov. 29, 2024 /PRNewswire/ — Imidex, a...
Aug 27, 2024 | Uncategorized
Computer Vision AI and Precision Genomic Collaboration Aims to Increase Early Detection Rates, Improving Survival Chances for Millions DENVER, Aug. 27, 2024 /PRNewswire/ — Imidex, a leading medical device company specializing in utilizing AI for...
Jul 11, 2024 | Uncategorized
DENVER, July 11, 2024 (GLOBE NEWSWIRE) — Spesana, a leader in personalized medicine technology for clinicians, diagnostic labs and pharmaceutical companies including the oncology specialty, and Imidex, developer of VisiRad XR, an FDA-cleared computer aided...
Apr 3, 2024 | Uncategorized
Company is evaluating strategic partners and potential acquirers who could potentially treat 50% more lung nodule patients in the U.S. and save billions of dollars annually in healthcare costs DENVER, April 03, 2024 (GLOBE NEWSWIRE) — Imidex, a pioneering...
Jan 12, 2024 | Uncategorized
IMIDEX is excited to announce that VisiRad XR is one of the first 510(k) cleared medical devices utilizing VertexAI by Google Cloud. We’re grateful for our continued partnership with Google and look forward to working with them into the future to detect lung...
Aug 22, 2023 | Uncategorized
IMIDEX’s CEO Richard Vlasimsky was interviewed by KOA 850AM radio in Denver to discuss the recent FDA clearance of VisiRad XR and how the use of AI tools like VisiRad XR can help identify potential lung cancers. Listen to the segment...
